McKesson (NYSE:MCK) Price Target Raised to $805.00 at UBS Group

McKesson (NYSE:MCK - Get Free Report) had its price target lifted by research analysts at UBS Group from $708.00 to $805.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's price objective indicates a potential upside of 12.91% from the stock's current price.

A number of other research firms also recently weighed in on MCK. Wells Fargo & Company upped their price target on McKesson from $641.00 to $691.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Cfra Research lowered shares of McKesson from a "moderate buy" rating to a "hold" rating in a research note on Friday, April 4th. Mizuho upped their target price on McKesson from $630.00 to $690.00 and gave the stock a "neutral" rating in a report on Thursday, April 3rd. Citigroup decreased their target price on McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Finally, Evercore ISI raised their target price on shares of McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $681.00.

McKesson Stock Up 0.9 %

Shares of MCK traded up $6.19 during trading hours on Tuesday, reaching $712.96. The stock had a trading volume of 43,587 shares, compared to its average volume of 886,542. McKesson has a 52 week low of $464.42 and a 52 week high of $728.32. The company has a market cap of $89.35 billion, a P/E ratio of 32.67, a P/E/G ratio of 1.29 and a beta of 0.49. The firm has a 50-day moving average of $669.64 and a 200 day moving average of $611.97.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. As a group, equities analysts expect that McKesson will post 32.77 earnings per share for the current year.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 188 shares of McKesson stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the completion of the transaction, the executive vice president now directly owns 1,051 shares of the company's stock, valued at approximately $640,679.09. This trade represents a 15.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $597.99, for a total value of $5,358,588.39. Following the sale, the chief executive officer now owns 60,664 shares in the company, valued at approximately $36,276,465.36. The trade was a 12.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,110 shares of company stock worth $10,855,706. Insiders own 0.11% of the company's stock.

Institutional Investors Weigh In On McKesson

Several institutional investors have recently bought and sold shares of MCK. Capital A Wealth Management LLC purchased a new position in McKesson during the fourth quarter worth about $26,000. Millstone Evans Group LLC bought a new position in shares of McKesson in the fourth quarter valued at approximately $28,000. Synergy Asset Management LLC purchased a new stake in shares of McKesson during the fourth quarter valued at approximately $32,000. Crews Bank & Trust bought a new stake in McKesson during the fourth quarter worth $33,000. Finally, Atala Financial Inc purchased a new position in McKesson in the fourth quarter worth $34,000. Institutional investors own 85.07% of the company's stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.